RenovoRx's Upcoming Presentation at ASCO Gastrointestinal Cancers Symposium
RenovoRx, Inc. (Nasdaq: RNXT), an innovative life-sciences company focused on creating targeted oncology therapies, has announced a significant milestone. The company will be showcasing its clinical data at the ASCO Gastrointestinal Cancers Symposium 2026. This prestigious event will be held in the vibrant heart of San Francisco, where leading experts in oncology gather to exchange knowledge and insights.
Details of the Clinical Findings to Be Presented
The findings to be presented stem from an important pharmacokinetic and pharmacodynamic sub-study of RenovoRx's ongoing Phase III TIGeR-PaC clinical trial. This trial, which is led by the esteemed Dr. Paula Novelli from the University of Pittsburgh Medical Center, aims to provide deeper insights into the effectiveness of a groundbreaking method of chemotherapy delivery.
The abstract, titled "Intra-arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-study of the TIGeR-PaC Phase 3 Clinical Trial," investigates the differences in drug levels between intra-arterially delivered gemcitabine via the patented RenovoCath device and the standard intravenous administration.
Understanding the Implications of Targeted Drug Delivery
Dr. Ramtin Agah, RenovoRx's Chief Medical Officer and one of the pivotal authors of this study, remarked on the potential impact of these findings. He emphasizes that the data supports the scientific rationale behind reduced side effects associated with the targeted delivery approach of the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform. This approach demonstrates that using the RenovoCath device can lead to lower systemic drug levels compared to traditional intravenous chemotherapy, potentially enhancing patient outcomes.
Key Dates and Session Information for Attendees
The ASCO GI symposium will be held from January 8 to 10, 2026. RenovoRx is scheduled to present its abstract on January 9, 2026, during two separate sessions: the first from 11:30 AM to 1:00 PM PT and again from 5:00 PM to 6:00 PM PT. For attendees wanting to catch this invaluable information, the presentation will take place at the Moscone West Building, and the abstract will be displayed on Poster Board Number K2 during Session Title: Poster Session B, which will encompass cancers of the pancreas, small bowel, and hepatobiliary tract.
A Closer Look at RenovoCath and Its Applications
RenovoCath, a pivotal device in RenovoRx's portfolio, is FDA-cleared and designed for targeted therapy delivery. It allows for the isolation of blood flow and precise delivery of therapeutic agents directly where they are needed within the vascular system. This device also serves applications such as temporary vessel occlusion, which enhances its use in different medical scenarios.
About the TIGeR-PaC Clinical Trial
The ongoing TIGeR-PaC clinical trial represents a promising avenue for patients suffering from locally advanced pancreatic cancer (LAPC). It is a comprehensive multi-center Phase III randomized trial that assesses the efficacy of the TAMP™ therapy platform, combining the advantages of the RenovoCath device for intra-arterial administration of gemcitabine, an established chemotherapy agent.
RenovoRx's Commitment to Innovative Cancer Solutions
RenovoRx, Inc. focuses on addressing significant unmet medical needs within oncology. Their patented therapy platform aims to provide improved therapeutic delivery to tumor sites while minimizing associated toxicities that come from traditional systemic therapies. With a mission to transform cancer care, RenovoRx endeavors to deliver effective solutions that address the specific bolstered demands of patients and healthcare providers alike.
The company is not only advancing its clinical trials but is also actively commercializing the RenovoCath device. In a remarkable achievement, RenovoRx reported the first commercial orders for the RenovoCath device and generated approximately $900,000 in revenue from initial sales. This milestone reflects the strong interest in targeted therapy approaches, as several prominent medical institutions are now implementing the RenovoCath in their treatment protocols.
Final Thoughts
With the cutting-edge research and clinical trials underway, RenovoRx is poised to make significant contributions to the field of oncology, particularly in targeted drug delivery and treatment efficacy. As they continue to explore the potential of the TAMP technology and the RenovoCath device, they are hopeful for what lies ahead in improving treatment options for patients battling advanced cancers.
Frequently Asked Questions
What is RenovoRx?
RenovoRx, Inc. is a life-sciences company focusing on developing targeted oncology therapies to improve cancer treatment outcomes.
What is the TIGeR-PaC trial about?
The TIGeR-PaC trial is a Phase III clinical study evaluating the safety and efficacy of intra-arterial gemcitabine delivery using the RenovoCath device for locally advanced pancreatic cancer.
Where will RenovoRx present its findings?
RenovoRx will present its findings at the ASCO Gastrointestinal Cancers Symposium 2026 in San Francisco.
What is the significance of the RenovoCath device?
RenovoCath is designed for targeted drug delivery, allowing for effective treatment directly at the tumor site while minimizing systemic exposure and side effects.
What are the anticipated benefits of the company's approach?
The company's targeted delivery system aims to offer reduced side effects and potentially improved efficacy compared to traditional systemic therapies.
